- Design
- Systematic review and meta-analysis of mainly uncontrolled studies
- Population
- 19 studies, 445 patients with relapsing or refractory lupus nephritis
- Primary outcome
- Complete, partial and overall renal response at 6, 12 and 24 months
- Effect
- Complete response 41% (95% CI 28 to 54) at 12 months; overall response 70%
This meta-analysis pooled 19 studies with 445 patients who received rituximab as rescue or add-on therapy for relapsing or refractory lupus nephritis. Most studies were uncontrolled.
Complete renal response was 33% at 6 months, 41% at 12 months and 42% at 24 months. Overall response, including partial, was about two-thirds throughout. Proteinuria fell by about 2.7 g per day and creatinine by about 12 micromol/L. Results were stable in sensitivity analyses.
Rituximab is widely used off-label when standard induction fails, and this puts realistic numbers on what to expect. Without control groups, it cannot show that rituximab does better than switching or intensifying another agent, and the authors call for comparative trials.
- Confirm adherence and repeat biopsy where appropriate before labelling lupus nephritis refractory.
- Consider rituximab as add-on or rescue therapy in relapsing or refractory lupus nephritis.
- Tell patients that about four in ten reached complete renal response in pooled studies, and most had some response.
- Check hepatitis B status and immunoglobulins before rituximab.
Why it matters
It gives clinicians and patients realistic expectations for a common off-label rescue strategy.
Don't overread it
Most included studies lacked a comparison group; the figures do not show rituximab is better than alternatives.
The statistics, in plain English
Pooled response rates have wide intervals (for example 26% to 60% at 24 months), reflecting small, varied studies. Without a control arm, some response may reflect natural fluctuation or other treatment changes.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free